Skip to main content

Table 1 Disease was reduced in EE treated WT and ERKO mice compared to their respective controls.

From: GPR30, but not estrogen receptor-α, is crucial in the treatment of experimental autoimmune encephalomyelitis by oral ethinyl estradiol

  

CDI

Onset

Peak

WT:

Ctrl

64.5 (± 2.5)

12.3 (± 0.4)

5.1 (± 0.1)

 

EE

54.0* (± 1.8)

12.0 (± 0.5)

4.8 (± 0.1)

ERKO:

Ctrl

60.5 (± 4.0)

11.7 (± 0.4)

4.8 (± 0.2)

 

EE

48.5* (± 3.1)

12.2 (± 0.4)

4.2* (± 0.2)

GPR30KO:

Ctrl

47.6 (± 5.3)

11.5 (± 0.4)

4.5 (± 0.3)

 

EE

51.2 (± 4.2)

11.0 (± 0.4)

4.6 (± 0.6)

  1. Cumulative disease index (CDI) was reduced in EE-WT and EE-ERKO mice compared to their respective control groups. Peak disease severity was only reduced in ERKO-EE mice. Onset did not differ between any EE and control groups. * indicates p < .03
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us